An interventional study of Omega-3 Fatty Acids and Semaglutide 0.25 mg in Type 2 Diabetes, Cardiovascular Disease and Omega-3 Fatty Acids, sponsored by University of Ulster. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by University of Ulster · Not applicable, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, none of them phase 3. omega-3 fatty acid · Diabetes Mellitus, Type 2.
Among the 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is one of 7 with no phase, and was the 14th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Institut de Recherches Cliniques de Montreal · Sites in Canada
Ages 45–74 · Healthy volunteers
Bangladesh Medical University · Sites in Bangladesh
Ages 25–75 · Men only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 77 across the 14 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
University of Ulster is the lead sponsor of 96 studies on the registry; 15 are open to participants now.
University of Ulster has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
2 of the studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07677995University of UlsterFree Fatty Acid Effects In Type 2 Diabetes | 2026-12 |
| NCT04485871Institut de Recherches Cliniques de MontrealTargeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Omega-3 fatty acids are natural fats found in foods such as oily fish and flaxseed. Omega-3 fatty acids have been found to have positive effects on cardiovascular health, but there is less evidence on if they can help manage blood glucose in individuals with both cardiovascular disease and type 2 diabetes.
This study will investigate whether the beneficial effects found in omega-3 fatty acids such as lowered blood glucose and reduced inflammation - both of which are important for managing type 2 diabetes and cardiovascular disease, can be beneficial for individuals with type 2 diabetes. As omega-3 fatty acids are already found naturally in food, and are already available as supplements, they could be a safe option to help manage these diseases.
The aim of this study is to investigate if omega-3 fatty acids can slow down the progression of type 2 diabetes and reduce the risk of cardiovascular disease in individuals with type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Placebo
Dietary Supplement: Omega-3 Fatty Acids
Dietary Supplement: Omega-3 Fatty Acids
Semaglutide is being used for comparison purposes only
Dietary Supplement: Omega-3 Fatty Acids · Drug: Semaglutide 0.25 mg
1500mg/day for 28 days
0.25mg weekly for four weeks
Receive placebo
To evaluate the change in fasting glucose from baseline after 28 days of treatment, compared to each treatment group and placebo.
Time frame: From baseline to 28 days of treatment
The change in insulin compared to placebo administration
Time frame: From baseline to 28 days of treatment
The change in HbA1c compared to placebo administration
Time frame: From baseline to 28 days of treatment
Glucose tolerance measurements during OGTT compared to placebo administration
Time frame: From baseline to 28 days of treatment
Area under the curve measurements during OGTT compared to placebo administration
Time frame: From baseline to 28 days of treatment
Plasma gut hormone concentrations (GLP-1, GIP, PYY, ghrelin, CCK and glucagon) compared to placebo administration
Time frame: From baseline to 28 days of treatment
Full lipid profile (cardiovascular risk markers) compared to placebo administration
Time frame: From baseline to 28 days of treatment
Inflammatory and cardiovascular markers compared to placebo administration
Biomarkers include inflammatory markers (C-reactive protein \[CRP\], pro- and anti-inflammatory cytokines) and cardiovascular risk markers
Time frame: From baseline to 28 days of treatment
Liver function tests (ALT and AST) compared to placebo administration
Time frame: From baseline to 28 days of treatment
Body mass index (BMI) compared to placebo administration
Weight (kg) and height (m) will be combined to report BMI in kg/m\^2
Time frame: From baseline to 28 days of treatment
Waist-to-hip circumference compared to placebo administration
Waist circumference (in cm between the lower rib and iliac crest) and hip circumference (in cm at the widest part of the hips/buttocks) will be combined to calculate waist-to-hip circumference
Time frame: From baseline to 28 days of treatment
Blood pressure compared to placebo administration
Time frame: From baseline to 28 days of treatment
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index compared to placebo administration
Insulin resistance will be measured by calculating HOMA-IR using the formula: HOMA-IR = fasting plasma glucose (mg/dL) x fasting plasma insulin/405. Higher values indicate greater insulin resistance. This is a derived continuous index with no fixed minimum or maximum value.
Time frame: From baseline to 28 days of treatment
Change in Omega-3 Index (EPA and DHA as a percentage of total fatty acids) compared to placebo administration
Time frame: From baseline to 28 days of treatment
Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 3 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omega-3 fatty acid
University of Ulster